CSRC Slams Auditor Zhongxingcai Guanghua With Fine for Jiangsu Wuzhong Audit Failures

CSRC Penalizes Auditor Over Jiangsu Wuzhong’s Inflated Revenues

China's Securities Regulatory Commission (CSRC) has imposed monetary penalties on Zhongxingcai Guanghua Certified Public Accountants (Special General Partnership) and two signing auditors for failing to exercise due diligence during the 2022 and 2023 annual audits of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd., a Shenzhen-listed drug manufacturer and distributor.

The regulator found that Jiangsu Wuzhong had used non-commercial trade transactions with related companies to artificially inflate revenues, costs and profits in both years. These sham deals also created non-operational related-party fund occupancies that were not disclosed in the company’s filings. Despite these material misstatements, Zhongxingcai Guanghua issued unqualified audit opinions for both years, earning total audit fees of RMB 2,075,471.68 (excluding VAT).

The CSRC investigation identified multiple failures in the audit process: the auditor did not test internal controls for the trade business at key subsidiaries, failed to maintain professional skepticism during management interviews, ignored inconsistencies between interview records and audit working papers, and overlooked anomalous contract numbers and pricing margins. Additionally, the firm did not act on abnormal bank account transactions and had deficiencies in auditing monetary funds and other current assets.

The regulator concluded that these lapses violated several Chinese auditing standards and that the audit reports contained false records. Zhongxingcai Guanghua was found to have breached Article 163 of the Securities Law, constituting a violation under Article 213(3). The signing CPAs, Yu Jun and Lou Jianan, were identified as directly responsible and face individual penalties alongside the firm.

What This Case Reveals About Audit Oversight and Industry Risk

Audit Quality Lapses That Matter

The CSRC’s specific findings make this case a textbook example of how auditors can miss orchestrated revenue fraud. The failure to test sales-and-receivables controls at subsidiaries executing the trade business suggests a fundamental breakdown in risk assessment: if the auditor could not verify that internal procedures actually existed for these high-risk transactions, the entire assurance model collapses. The interview weaknesses—such as accepting responses at face value without checking the commercial logic of the trades or verifying interviewees’ identities—signal a lack of professional skepticism.

Regulatory Context and Signal to the Market

This penalty arrives amid a broader CSRC campaign to tighten audit oversight, especially for small and mid-cap firms where revenue recognition and related-party dealings are the most common fraud vectors. By naming the specific audit standards violated and publicly detailing the deficiencies, the CSRC is not just punishing one firm but signaling to all auditors that mechanical compliance is insufficient; they must challenge management’s assertions when red flags appear. The case also highlights the regulator’s willingness to penalize individual signatories, not just entities, raising career risk for CPAs.

Impact on Jiangsu Wuzhong and Its Investors

For the listed company, the CSRC’s separate investigation into the financial misstatements likely means its own penalties and potential restatements are coming, which could erode investor confidence and trigger shareholder lawsuits. The fact that two full years of financials were materially misstated will cast a long shadow over any forward-looking statements or restructuring plans. Bondholders and lenders reliant on audited statements now have to reassess credit risk, while equity investors face a stock price correction if markets had priced in a cleanup that now appears more extensive.

Next Steps for Audit Firms, Listed Companies and Investors

• Audit committees at listed companies should immediately verify whether their external auditor has adequate procedures for testing the commercial substance of high-volume trade and service transactions, especially with related parties. If not, demand a supplemental review before signing the next audit engagement.
• Investors holding Jiangsu Wuzhong shares or bonds should prepare for restated financial results that could show significantly lower revenue and equity. The CSRC’s mention of “non-operational fund occupancies” suggests potential recoverability issues; historical cash flow statements are now unreliable.
• Other Chinese audit firms should treat this sanction as a compliance wake-up call and update their internal training on applying professional skepticism during interviews and transaction testing. In particular, any inconsistency between recorded interviews and working papers must be escalated to an engagement quality reviewer.
• Regulatory risk officers at brokerages and fund managers should flag that companies audited by Zhongxingcai Guanghua may come under heightened CSRC review, potentially delaying IPOs or refinancing plans that rely on those audit opinions.